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Abstract 
CD81 plays a central role in a variety of 
physiological and pathological processes. Recent 
structural analysis of CD81 indicates that it 
contains an intramembrane cholesterol-binding 
pocket and that interaction with cholesterol may 
regulate a conformational switch in the large 
extracellular domain of CD81. Therefore, CD81 
possesses a potential cholesterol sensing 
mechanism; however, its relevance for protein 
function is thus far unknown. In this study we 
investigate CD81 cholesterol sensing in the 
context of its activity as a receptor for hepatitis 
C virus (HCV). Structure-led mutagenesis of the 
cholesterol-binding pocket reduced CD81-
cholesterol association, but had disparate effects 
on HCV entry, both reducing and enhancing 
CD81 receptor activity. We reasoned that this 
could be explained by alterations in the 
consequences of cholesterol binding. To 
investigate this further we performed molecular 
dynamic simulations of CD81 with and without 
cholesterol; this identified a potential allosteric 
mechanism by which cholesterol binding 
regulates the conformation of CD81. To test this, 
we designed further mutations to force CD81 
into either the open (cholesterol unbound) or 
closed (cholesterol bound) conformation. The 
open mutant of CD81 exhibited reduced receptor 
activity whereas the closed mutant enhanced 
activity. These data are consistent with 
cholesterol sensing switching CD81 between a 
receptor active and inactive state. CD81 
interactome analysis also suggests that 
conformational switching may modulate the 
assembly of CD81-partner protein networks. 
This work furthers our understanding of the 
molecular mechanism of CD81 cholesterol 
sensing, how this relates to HCV entry and 
CD81’s function as a molecular scaffold; these 
insights are relevant to CD81’s varied roles in 
both health and disease.  
 
 
Introduction 
Binding of the E2 glycoprotein of hepatitis C 
virus (HCV) to the large extracellular loop of 
CD81 is a defining event in the entry of HCV 
(1) and is targeted by multiple broadly 
neutralising antibodies, thus placing this 
molecular interaction at the forefront of current 
HCV vaccine development (2, 3). Whilst the 
importance of CD81 in HCV entry is well 
established, the precise details of E2-CD81 
interaction have yet to be defined and the 
molecular determinants of CD81 receptor 
activity are only partially understood (4).  
 
CD81 is a prototypical member of the 
tetraspanin superfamily. Tetraspanins are small 
integral membrane proteins, defined by their 
four transmembrane domains separated by 
intra/extracellular loops. Highly-conserved 
cysteine residues stabilise tetraspanin tertiary 
structure through disulphide bridges, and 
provide sites for post-translational 
palmitoylation, which influences tetraspanin 
membrane segregation (5, 6). 
 
Largely without cognate ligands, tetraspanins 
participate indirectly in a wide variety of cell-
biological processes through their interactions 
with partner proteins, which they organise into 
functional complexes (7, 8). For example, CD81 
facilitates the assembly of the B-cell receptor 
complex and is therefore essential for normal 
antibody responses. CD81 performs this role via 
partnership with CD19; first by chaperoning 
CD19 through the secretory pathway and then 
by dictating its cell surface distribution, 
permitting proper assembly of the B-cell 
receptor complex upon activation (9–12). 
Through other molecular partnerships CD81 has 
been implicated in additional physiological 
processes such as T-cell receptor signalling, cell 
migration, growth factor signalling, sperm-egg 
fusion and most recently, biological ageing, 
potentially through its interaction with TMEM2 
(13–19). 
 
Aside from these physiological functions, CD81 
is also commandeered by diverse infectious 
pathogens. It participates in the cell-surface 
assembly of both human immunodeficiency 
virus (HIV) and influenza A virus; a function 
that may be linked to the apparent affinity of 
CD81 for membrane structures with high 
curvature (20–23). CD81 also negatively 
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regulates SAMHD1 function, resulting in 
increased intracellular pools of dNTPs, which in 
turn favours HIV reverse transcription (24). 
Finally, CD81 is critical for the entry of HCV 
and Plasmodium sporozoites into human 
hepatocytes (1, 25). In summary, CD81 
performs molecular scaffolding function in a 
variety of pathways; a greater understanding of 
its molecular characteristics will provide novel 
insights into both physiological and pathological 
processes. 
 
The recent crystal structure of CD81, the first of 
any tetraspanin, has provided a novel 
perspective on its molecular biology (26). 
CD81’s four helical transmembrane domains are 
arranged in a loose bundle forming an inverted 
conical shape. Curiously, the transmembrane 
domains enclose a central intramembrane cavity 
filled by a single molecule of cholesterol, which 
is coordinated by hydrogen bonding to the side 
chains of inward-facing amino acids. Whilst this 
observation may have arisen due to the presence 
of cholesterol in the crystallisation buffer, 
Zimmerman et. al. use biochemical experiments 
to demonstrate physical association of CD81 
with cholesterol (26). Moreover, this finding is 
consistent with other reports linking cholesterol 
to tetraspanin biology (27, 28). 
 
Whereas the minor extracellular domain (EC1) 
was not resolved in the crystal structure  (PBD 
5TCX (26)), CD81’s major extracellular domain 
(EC2) was found to be roughly parallel to the 
plane of the plasma membrane, analogous to a 
lid sitting on top of the bundle of transmembrane 
domains (Fig. 1A and Fig S2A). Overall, CD81 
adopts a compact structure that is likely to 
project only a few nanometers from the cell 
surface. However, using molecular dynamic 
simulations Zimmerman et. al. demonstrated that 
the EC2 of CD81 has a propensity to flip up into 
an extended open conformation (Fig S2A). 
Furthermore, removal of cholesterol from the 
intramembrane cavity during the simulations 
increased the frequency of conformational 
switching, suggesting an allosteric link between 
cholesterol binding and CD81 conformation. 
These observations indicate that CD81 may have 
an, as yet unappreciated, function as a 
cholesterol sensor; this feature is likely to be 
important for its role as a scaffold for events 
occurring at cellular membranes. 
 
Whilst the precise molecular interaction of HCV 
E2 with the EC2 of CD81 has yet to be 
structurally defined, the relevant protein 
domains have been identified (29–34). The 
CD81 binding site of HCV E2 comprises 
discontinuous protein regions, brought together 
in the 3D structure of the glycoprotein; these 
interact with helices D and E of CD81’s EC2, 
which are presented at the apex of CD81’s 
closed compact structure. Antibodies that 
prevent this interaction block HCV entry, and 
cells without CD81 are completely resistant to 
infection (35–44). The ability of CD81 to recruit 
molecular partners is also likely to be important 
for HCV infection; indeed, other HCV entry 
factors constitutively associate with CD81 (8, 
45). Significantly, HCV entry also seems to be 
closely linked to cell-surface cholesterol 
transport: three cholesterol-transporting proteins 
(SR-B1, LDLR and NPC1L1) have been 
implicated in the process (46). Notably, the 
cholesterol transporter scavenger receptor B-1 
(SR-B1) naturally associates with CD81 and 
also modulates the CD81-dependent invasion of 
Plasmodium sporozoites into hepatocytes (8, 47, 
48). 
 
The biology of both CD81 and HCV converge 
on plasma membrane cholesterol; therefore, we 
set out to investigate how CD81’s interaction 
with cholesterol impacts HCV infection. First, 
we mutated residues within the cholesterol 
binding pocket of CD81. Whilst all of the tested 
mutations reduced CD81-cholesterol association 
they had varying effects on HCV, both 
decreasing and increasing virus entry. This 
suggests the cholesterol binding pocket of CD81 
is important for HCV infection, but viral entry 
may not be directly dependent on cholesterol 
association. We performed multiple independent 
molecular dynamics (MD) simulations of CD81 
behaviour with and without cholesterol. In 
support of the report by Zimmerman et. al., we 
demonstrate a cholesterol-dependent 
conformational switch of CD81; this is 
consistent with the notion of cholesterol sensing 
by CD81. These experiments identified a 
potential hinging between CD81’s EC2 and 
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transmembrane domains. We designed 
mutations to alter this motion and, therefore, 
disrupt CD81’s cholesterol sensing mechanism. 
Mutations that are predicted to confer the open 
conformation (i.e. the cholesterol unbound state) 
reduced HCV entry, whereas mutations that 
confer the closed (i.e. cholesterol bound state) 
enhanced HCV entry. Further characterisation of 
these mutants demonstrate that they exhibit 
normal cell surface expression and distribution, 
and retain the ability to chaperone CD19 to the 
cell surface. However, the open mutant of CD81 
exhibits reduced interaction with HCV E2. We 
also use diverse cell culture proficient HCV to 
demonstrate that cholesterol-binding and open 
conformation mutants of CD81 do not support 
authentic viral replication. This study provides 
further insight into the molecular mechanism of 
cholesterol sensing by CD81 and demonstrates 
that this activity is important for HCV infection. 
Results 
Mutations in the cholesterol-binding 
pocket of CD81 modulate HCV entry. 
The crystal structure of CD81 (PBD 5TCX (26)) 
reveals an intramembrane cavity bounded by the 
four transmembrane domains; this contains a 
single molecule of cholesterol, which is 
coordinated by hydrogen bonding to the side 
chains of two residues, N18 and E219 (Fig. 1A). 
We designed a series of mutants to disrupt this 
interaction; E219A and E219Q, that were 
previously demonstrated to reduce CD81-
cholesterol association (26), and an N18A 
E219A double mutation, which should remove 
all possibility of hydrogen bonding to 
cholesterol. Many of the inward-facing residues 
of CD81’s intramembrane cavity have small side 
chains (e.g. alanine, valine, glycine), this creates 
a binding pocket to accommodate cholesterol. 
Therefore, we also mutated four inward facing 
residues to tryptophan (V68W M72W A108W 
V212W), the side chain of which includes a 
bulky indole group. Structural modelling 
predicts that these tryptophan residues will fill 
the cholesterol-binding pocket, whilst 
maintaining the hydrophobic nature of the 
transmembrane domains (Fig. 1B). We 
introduced each of the cholesterol-binding 
pocket mutants into Huh-7 CD81 KO cells by 
lentiviral transduction and confirmed that their 
cell-surface expression was equivalent to WT 
CD81 (Fig. 1C).  
 
Zimmerman et. al. previously demonstrated 
CD81-cholesterol association by the addition of 
exogenous cholesterol to purified CD81 (26); we 
corroborated this by examining the interaction of 
CD81 with endogenous plasma-membrane-
resident cholesterol. Huh-7 CD81 KO cells 
transduced with WT CD81 or empty vector 
control, were surface labelled with anti-CD81 
mAb and then lysed for immunoprecipitation. 
Following pull-down of CD81-mAb complexes 
with protein G beads we assayed the 
concentration of free, unesterified, cholesterol; 
this is the form of cholesterol found in cellular 
membranes (49). Our negative control 
determined the limit of detection (≥0.05µM), 
whilst our positive control demonstrated the 
accuracy of the assay (Fig. 1D). In the pull-
down from cells transduced with empty vector 
control we did not measure any free cholesterol, 
whereas cholesterol was readily detectable in the 
pull-down from cells expressing WT CD81.  
 
Next, we went on to measure cholesterol 
association with the binding pocket mutants; 
each of the mutants exhibited a reduction in co-
immunoprecipitated cholesterol (Fig. 1E). 
Notably, this experiment cannot discriminate 
between cholesterol that is directly associated 
with CD81 and peripheral cholesterol that is 
indirectly extracted during lysis and 
immunoprecipitation. Therefore, it is possible 
that the reduction in cholesterol concentration in 
each of our mutant pull downs represents a 
complete loss of specific cholesterol binding; 
this, however, cannot be determined. 
Nonetheless, these data are consistent with 
specific association between plasma-membrane 
cholesterol and CD81, and that this interaction 
can be reduced by mutating residues in the 
cholesterol-binding pocket of CD81. 
 
We challenged Huh-7 cells expressing each 
mutant with a panel of HCV pseudoparticles 
(HCVpp); these are lentiviral reporters 
pseudotyped with the E1E2 glycoproteins of 
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diverse strains of HCV, as such this system 
recapitulates the events of HCV entry (50, 51). 
Whilst the various cholesterol pocket mutants 
possessed identical cellular expression and 
similar deficiency in cholesterol association (Fig 
1C & E) they exhibited differential HCV 
receptor activity (Fig 1F & G). Of the mutations 
that disrupt hydrogen bond formation with 
cholesterol, E219Q and N18A E219A reduced 
HCV entry by ~50%, whilst the E219A single 
mutant had equivalent receptor activity to WT 
CD81. Notably, the V68W M72W A108W 
V212W mutant, in which the binding pocket is 
filled with bulky tryptophan side chains, 
enhanced HCV entry by ~50%. These data 
demonstrate that mutations within the 
cholesterol-binding pocket of CD81 have the 
capacity to both negatively and positively 
modulate HCV entry. However, given that the 
level of cholesterol association did not correlate 
with receptor activity, it is unlikely that HCV is 
directly dependent on cholesterol occupying the 
intramembrane binding pocket of CD81.  
SR-B1 does not enhance cholesterol 
loading into CD81. 
CD81 constitutively associates with SR-B1 (7), 
a cell surface cholesterol transporting protein, 
which possesses a central hydrophobic tunnel 
through which cholesterol can be conveyed from 
high-density lipoproteins directly to the plasma 
membrane (52, 53). Moreover, this lipid 
transport function has been demonstrated to 
modulate the role of CD81 in HCV and malaria 
entry (48, 54). These observations led us to 
hypothesise that SR-B1 may directly load 
cholesterol into the binding cavity of CD81. 
Indeed, when human SR-B1 is over-expressed in 
CHO cells total cellular cholesterol levels 
double (Fig S1A). However, co-over-expression 
of SR-B1 did not alter CD81-associated 
cholesterol levels, as assessed by 
immunoprecipitation (Fig S1B). This is despite 
the detection of SR-B1-CD81 complexes in the 
pull down. As a further test we evaluated CD81-
cholesterol association in Huh-7 SR-B1 KO 
cells with and without add-back of exogenous 
SR-B1 (Fig S1C); we measured no difference in 
CD81-cholesterol association. Therefore, this 
hypothesis is not supported by the data. 
Cholesterol regulates conformational 
switching of CD81. 
Zimmerman et. al. reported that cholesterol 
binding regulates a switch in the EC2 of CD81 
from a closed conformation (cholesterol bound) 
to an open conformation (cholesterol unbound) 
(Fig S2). This provides a molecular mechanism 
by which CD81 may sense cholesterol in cellular 
membranes. We reasoned that cholesterol 
sensing, rather than cholesterol binding in and of 
itself, may provide a mechanism by which the 
binding pocket mutants may modulate HCV 
entry. To investigate this further we used 
molecular dynamics (MD) simulation: an in 
silico methodology for predicting the 
conformational dynamics of proteins, both at 
steady state and after perturbations such as 
ligand removal or mutagenesis (55, 56). We 
conducted five independent 500ns MD 
simulations of CD81 with and without 
cholesterol and quantified the conformational 
state of the EC2. In the presence of cholesterol 
CD81 remained largely in a closed 
conformation, similar to that seen in the crystal 
structure, whereas in the absence of cholesterol 
the EC2 had a propensity to adopt a more 
extended open conformation. This was 
particularly apparent in a hinging motion 
between helix E of the EC2 and transmembrane 
domain 4 (TMD4) (Fig 2A). We therefore 
quantified the change in angle around this hinge 
in each simulation, using the angle adopted in 
the crystal structure as a reference (Fig 2B). In 
the absence of cholesterol, 3/5 simulations 
demonstrated clear and sustained extension of 
the hinge between the EC2 and TMD4. In the 
presence of cholesterol the angle of the hinge 
fluctuated in some simulations but provided 
little evidence of a persistent conformational 
switch. To further quantify this we calculated 
the cumulative time spent in the extended 
conformation across all five simulations, using 
an angle of 25° as a threshold (Fig 2C). This 
analysis suggests that in the absence of 
cholesterol CD81 is ~3 times more likely to be 
found in the open conformation.  
 
In the cholesterol bound crystal structure of 
CD81 the hinge between the EC2 and TMD4 is 
stabilised in a closed conformation by a salt-
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5 
bridge between D196 (in helix E of the EC2) 
and K201 (at the top of TMD4) (Fig S2B). 
Indeed, we observed interaction between these 
residues during our MD simulations in the 
presence of cholesterol (Fig 2A, top inset). 
However, without cholesterol CD81 adopts the 
open conformation, in which these residues are 
orientated on opposite sides of a continuous 
alpha-helix (Fig 2A, bottom inset). To examine 
this further we measured the distance between 
D196 and K201 during each simulation (Fig 
2D). In the presence of cholesterol the distance 
between D196 and K201 fluctuates, nonetheless 
they remain in close proximity and frequently 
reach the short distances (<10Å) at which 
electrostatic interactions and hydrogen bonding 
can occur (57). By contrast, in the absence of 
cholesterol these residues are consistently >10Å 
apart, indicating a change in orientation. To 
directly compare the experimental conditions we 
calculated the average distance between D196 
and K201; we found the value to be significantly 
higher in simulations without cholesterol (Fig 
2E). 
 
Taken together, these data are consistent with 
the reports of Zimmerman et. al. and support the 
notion of a cholesterol-dependent 
conformational switch in CD81. Moreover, our 
MD simulations predict that absence of 
cholesterol disrupts stabilising interactions 
across the EC2-TMD4 hinge, presumably 
through allosteric reorientation of amino acid 
side chains. This relationship provides a 
potential molecular mechanism for cholesterol 
sensing by CD81.  
Conformational switch mutants modulate 
HCV entry. 
To investigate whether the conformational 
switch required for CD81 cholesterol sensing is 
relevant to HCV entry we mutated both D196 
and K201 to alanine, therefore, preventing the 
possibility of interactions between these residues 
stabilising the EC2-TMD4 hinge. We would 
predict that the D196A K201A mutant would be 
more likely to adopt an open conformation, 
irrespective of the cholesterol binding status of 
CD81. To test this, we performed five 
independent MD simulations with the D196A 
K201A open mutant in the presence of 
cholesterol. In line with our expectations, the 
EC2-TMD4 hinge exhibited persistent opening 
in 2/5 simulations; consequently the D196A 
K201A was ~2 times more likely to be found in 
the open state (Fig 3 A & B). To further examine 
the effect of these mutations we also measured 
the distance between residues 196 and 201 
during the simulations (as in Fig 2D). In the 
D196A K201A open mutant the residues were 
consistently ~10Å apart; this was significantly 
further apart than WT CD81. This would 
suggest that mutagenesis has successfully 
prevented stabilising interactions across the 
EC2-TMD4. We introduced the CD81 D196A 
K201A open mutant into Huh-7 CD81 KO cells 
and challenged them with HCVpp; the N18A 
E219A cholesterol binding mutant was also 
included as a point of comparison (Fig 3D & E). 
D196A K201A exhibited poor receptor activity 
for all tested HCV strains and was statistically 
indistinguishable from the cholesterol binding 
mutant.  
 
The open conformation of CD81 reported by 
Zimmerman et. al. (Fig S2A) is stabilised by a 
salt bridge between K116 and D117, which sits 
around a hinge between helix A of the EC2 and 
TMD3. We mutated these residues to destabilise 
the putative open state and, therefore, create a 
closed mutant of CD81 (Fig S2C); we tested this 
alongside the cholesterol binding and open 
mutants in the HCVpp assay. The K116A 
D117A mutant displayed a consistent 
enhancement of receptor activity (Fig 3D). 
 
The fact the D196A K201A open mutant 
phenocopies the N18A E219A cholesterol 
mutant suggests that they both reduce CD81 
receptor activity by inducing conformational 
opening. Whereas the opposite effect was 
observed for the K116A D117A mutant, which 
is expected to spend more time in the closed 
conformation. Therefore, these data support a 
model in which HCV entry is dependent on the 
cholesterol-mediated closed conformation of 
CD81. 
 by guest on O
ctober 2, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
6 
Residues that contribute to cholesterol 
sensing are highly conserved. 
CD81 is found in all vertebrates, Figure S3A 
displays the structure of CD81 colour coded for 
its amino acid conservation across vertebrates; 
the transmembrane domains and hinge regions 
of the EC2 display high conservation, whilst the 
apex of the EC2 exhibits increased diversity. 
This suggests that the outward-facing apex is 
under positive selection to drive new 
interactions and/or to escape pathogen binding 
(58), whilst the lower region of the protein 
remains conserved to maintain residues that are 
essential for basic protein function. If cholesterol 
sensing and conformational switching is an 
important feature of CD81 we may expect high 
conservation at the residues that regulate this 
process. Figure S3B is a phylogenetic tree 
constructed from representative vertebrate CD81 
protein sequences and annotated to show the 
degree of conservation observed for the set of 
mutated residues described above. The residues 
found in the cholesterol-binding pocket and the 
conformation-switching residues are all 
conserved, suggesting functional importance. 
Notably, the residues at 116 & 117 and 196 & 
201 maintain the potential for salt bridge 
formation in 15/15 and 13/15 of the 
representative sequences; salt bridges often 
stabilise conformational intermediates of a 
protein. As a point of comparison we include 
F186, which is presented at the apex of CD81 
and is critical for HCV binding (34, 59); like 
much of the EC2, this position exhibits low 
conservation, consistent with the CD81-
dependent species specificity of HCV infection.  
CD81 mutants retain normal trafficking 
and CD19 chaperone function. 
CD81 participates in diverse cell biological 
processes via its interactions with various 
binding partners (6); for instance, CD81 is 
critical for B-cell receptor signalling by 
chaperoning CD19 through the secretory 
pathway (10–12). Therefore, we evaluated the 
cellular distribution and chaperone function of 
the cholesterol sensing/conformational switch 
mutants to determine if this correlated with HCV 
receptor activity. In all subsequent experiments, 
as an additional control, we included an F186A 
mutant that is unable to bind HCV E2 and does 
not support virus entry (34, 59).  
 
When expressed in Huh-7 CD81 KO cells each 
of the mutants exhibit equivalent cell surface 
expression by flow cytometry (Fig 4Ai) and 
display no overt changes in cell surface 
distribution (Fig S4A). This suggests that the 
mutant’s receptor activities are not correlated 
with trafficking deficiencies. To assess 
chaperone function, we recapitulated CD81-
dependent trafficking of CD19 in Huh-7 cells. 
Fig S4B displays exogenous CD19 expression in 
Huh-7 cells +/- CD81, as assessed by 
fluorescence microscopy; no cell surface CD19 
is detectable in Huh-7 CD81 KO cells, despite 
equivalent total cellular expression of CD19 (Fig 
S4C). Fig 4Aii displays CD81-dependent cell 
surface expression of CD19 in Huh-7 cells. Each 
of the mutants maintains the ability to chaperone 
CD19 to the plasma membrane; these data 
indicate normal cell surface localisation for each 
of the mutants.  
 
CD81 facilitates HCV entry through interaction 
with the major viral glycoprotein E2. This can 
be examined experimentally using soluble E2 
glycoprotein (sE2); whilst this is the least 
authentic system available to study HCV entry 
(sE2 is presented without its partner protein, E1, 
and not in the context of a virion) it is the only 
tool available to directly assess E2-CD81 
interactions at the cell surface.   
 
sE2 binding can be conferred to CHO cells by 
introduction of HCV receptors (CD81 or SR-B1) 
(60). Therefore, we transduced CHO cells with 
the CD81 mutants and assessed binding of sE2 
from the prototypical J6 and H77 strains. Figure 
4Bi displays flow cytometry histograms of anti-
CD81 mAb binding to each mutant, 
demonstrating equivalent CHO cell surface 
expression. Fig 4Bii provides representative 
plots of J6 sE2 binding to CHO-CD81 cells; 
note that whilst WT CD81 confers robust 
binding, the F186A mutant displays no 
interaction with E2. In this context, the N18A 
E219A cholesterol and K116A D117A closed 
mutants exhibit similar sE2 binding to that of 
WT CD81, whereas the D196A K201A open 
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7 
mutant has moderately reduced sE2 binding. 
This is quantified for both J6 and H77 sE2 in Fig 
4C.  
 
These data are not in particularly good 
agreement with the viral entry levels measured 
using HCVpp (Fig 3). Although the low receptor 
activity of D196A K201A is somewhat 
correlated with its ability to bind sE2, there is a 
disparity in effect sizes: e.g. D196A K201A 
exhibits only ~20% receptor activity for H77 
HCVpp (Fig 3D) but retains ~80% binding to 
H77 sE2 (Fig 4C). Therefore, whilst it remains 
possible that differences in sE2 binding to CD81 
mutants may contribute to their ability to support 
virus entry, it is likely that there is an additional 
determinant of receptor activity. 
CD81 cholesterol sensing is important for 
infection by authentic HCV. 
Whilst the HCVpp and sE2 experimental 
systems allow the direct evaluation of HCV 
entry and receptor interaction, they present the 
viral glycoproteins in unphysiological contexts. 
Therefore, to complement and corroborate these 
experiments we assessed CD81 receptor activity 
using the HCV cell culture model (HCVcc); this 
generates native HCV particles, which have the 
unusual property of being enriched in lipids and 
associated with host lipoprotein components (36, 
61–64). 
 
As before we transduced Huh-7 CD81 KO cells 
with each of our CD81 mutants and then 
challenged with J6/JFH HCVcc, quantifying the 
resultant infection by microscopy. Untransduced 
cells were completely resistant to HCVcc 
infection, whereas cells expressing WT CD81 
were readily infected (Fig 5A). Much like the 
HCVpp system, the N18A E219A cholesterol-
binding mutant and the D196A K201A open 
mutant display reduced ability to support 
HCVcc infection (Fig 5B). However, in this 
context the K116A D117A closed mutant failed 
to enhance infection, as we observed using 
HCVpp. The F186A E2 binding mutant 
exhibited minimal receptor activity. We also 
challenged CD81 expressing cells with a panel 
of HCVcc luciferase reporter viruses bearing the 
glycoproteins of diverse HCV strains from 
genotypes 1, 2, 3, 4 and 5 (Fig 5C). These data 
support our findings with J6/JFH HCVcc: N18A 
E219A and D196A K201A phenocopy each 
other, being poor receptors for HCV, whereas 
the K116A D117A mutant was equivalent to 
WT CD81. As an additional control we 
evaluated the effect of mutant CD81 on an HCV 
subgenomic replicon (SGR); this is a truncated 
HCV genome that lacks the structural proteins 
and, therefore, does not produce virus particles, 
but allows the processes of HCV translation and 
genome replication to be studied in isolation 
(65). In this system the cells expressing CD81, 
whether WT or mutant, supported JFH-1 SGR 
replication at a similar level to cells without 
CD81; this is expected, given that CD81 is 
thought to act during virus entry. It also 
demonstrates that the CD81 phenotypes 
observed using the HCVcc systems cannot be 
attributed to HCV translation or replication, and 
must be a consequence of virus entry (Fig S5). 
In summary, mutants that alter CD81 cholesterol 
binding and/or conformational switching are 
poor receptors for HCVcc particle entry; this 
demonstrates that cholesterol sensing by CD81 
is important for HCV infection.  
Conformational switch mutants have 
altered protein interaction networks. 
Like any tetraspanin, the activity of CD81 is 
defined by its molecular partnerships. Indeed,  
the interactions of CD81 with SR-B1, CLDN1 
and EGFR are important for HCV entry, whilst 
CD81’s physiological functions are driven by 
various other partnerships with, for example, 
integrins (cell migration) and CD3 (T-cell 
regulation) (66, 67). The molecular mechanisms 
of tetraspanin-partner interactions remain poorly 
understood. To investigate the contribution of 
cholesterol binding and/or conformational 
switching to CD81’s interaction network we 
performed co-immunoprecipitation (co-IP) using 
an anti-CD81 EC2 mAb, followed by label-free 
quantitative (LFQ) mass spectrometry on cells 
expressing CD81 variants. Interaction partners 
were identified by statistical comparison of LFQ 
intensities from cells expressing CD81 to control 
cells without CD81. We identified multiple 
interacting proteins for WT CD81, consistent 
with our previous investigations of the CD81 
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interaction network, including well-described 
partners such as SR-B1 (SCARB1), claudin-1 
(CLDN), epidermal growth factor receptor 
(EGFR), transferrin receptor (TFRC), calpain-5 
(CAPN5), integrin β-1 (ITGB1) and CD151 
(Figure 6A & Supplementary File 1). Figure 6B 
displays enrichment values for these 
aforementioned proteins in co-IP/MS analyses of 
CD81 expressing versus control cells (7, 8). 
Intensity values were similar for most of these 
selected proteins, suggesting comparable 
interactions with WT and mutant CD81. 
Moreover, interactions with reported HCV entry 
factors (SR-B1, claudin-1, EGFR, transferrin 
receptor and calpain-5 (8, 68–71)) were not 
correlated to receptor activity. For example, 
EGFR association was reduced for both the 
D196A K201A (open) and K116A D117A 
(closed) mutants (Figure 6A ,Figure S6 & 
Supplementary File 1). Nonetheless, these 
mutants have opposing activities in the 
infectivity assays (Figure 3 & 5), suggesting that 
EGFR interaction is not a determinant of these 
phenotypes. In addition to this focussed analysis 
of well-described interaction partners, we also 
compared the entire interaction network for each 
of the CD81 mutants (Figure 6C). The 
cholesterol binding mutant (N18A E219A) was 
largely unchanged with >90% of interactions 
maintained. In contrast, the conformational 
switch mutants exhibit a 40-50% loss of 
interactions; cross comparison revealed a degree 
of polarisation between these mutants, 
suggesting the loss of different subsets of 
partnerships. These data suggest that the EC2 of 
CD81 is important for partner interactions, as 
has been recently demonstrated for CD19 (72). 
Moreover, the conformation of the EC2 (either 
open or closed) may regulate protein network 
assembly. However, this experiment did not 
provide evidence of cholesterol-mediated 
regulation of partnerships, and we were unable 
to identify specific interaction(s) that correlated 
with HCV receptor activity. 
Discussion 
Like many tetraspanins, CD81 partners with a 
variety of cell surface components to contribute 
to various physiological and pathological 
processes (5, 6). The CD81 crystal structure 
solved by Zimmerman et. al., provided a new 
perspective on tetraspanin biology (26) and 
proposed two novel features that may be highly 
relevant for protein function: i) CD81 is able to 
bind cholesterol in a cavity formed by its 
transmembrane domains and ii) the EC2 of 
CD81 undergoes a cholesterol-dependent 
conformational switch between a compact 
‘closed’ form to an extended ‘open’ 
configuration. These properties bestow CD81 
with a potential cholesterol-sensing mechanism; 
this is particularly interesting given the long-
standing link between tetraspanin biology and 
cholesterol (7, 27, 28).  
 
How cholesterol sensing contributes to CD81 
function was, thus far, unclear. In this study, we 
investigated these structural features in the 
context of a well-characterised biological 
activity: CD81’s ability to mediate HCV entry. 
The importance of our work is two-fold; it 
provides a greater understanding of the 
molecular basis of CD81 cholesterol sensing, 
and also demonstrates that these features are 
important for CD81’s ability to support HCV 
infection. 
 
First we mutated residues within the cholesterol-
binding pocket of CD81 (Fig 1); these were 
designed to either directly prevent CD81-
cholesterol interaction or to fill the binding 
pocket with bulky side-chains, therefore 
negating cholesterol binding. We demonstrated 
co-immunoprecipitation of CD81 and free 
cholesterol. This is good evidence of association 
between CD81 and plasma membrane-resident 
cholesterol. We observed a significant reduction 
in cholesterol association for each of our binding 
pocket mutants; this supports the notion of 
specific retention of cholesterol in CD81. 
However, cholesterol association did not reach 
background levels; this may indicate some non-
specific association (due to detergent extraction) 
or that the mutations were insufficient to 
completely prevent capture of cholesterol.  
 
Despite their equivalent deficiency in cholesterol 
association the binding pocket mutants had 
disparate activity in the HCVpp assay, being 
either neutral (E219A), detrimental (E219Q and 
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N18A E219A), or beneficial (V68W M72W 
A108W V212W) to HCV entry. This suggests 
that receptor activity is not determined directly 
by the ability to bind cholesterol and may, 
instead, be dependent on the 
molecular/structural consequences of cholesterol 
binding. Interestingly, the enhancement of HCV 
entry by the V68W M72W A108W V212W 
mutant (and its phenotypic similarity to the 
K116A D117A closed mutant) may indicate that 
filling the binding pocket of CD81 with bulky 
side chains, in fact, mimics cholesterol binding. 
 
Following these experiments we hypothesised 
that cholesterol-sensing, with its associated 
conformational change (26), may underpin the 
relationship between the cholesterol-binding 
pocket and HCV entry. To investigate this 
further we performed MD simulations of CD81 
conformational dynamics; these experiments 
shed light on the potential molecular 
mechanisms of CD81 cholesterol sensing. In 
particular we observed a hinging motion 
between the EC2 and TMD4 of CD81 that was 
more likely to occur in the absence of 
cholesterol (Fig 2). Furthermore, in the CD81 
crystal structure (which includes cholesterol) 
this hinge is conformationally locked in the 
closed orientation by a salt bridge between D196 
and K201. By measuring the distance between 
D196 and K201 throughout the simulations we 
demonstrated that in the absence of cholesterol 
these residues are reorientated such that 
stabilising interactions are unlikely to occur. 
Therefore, we propose that cholesterol sensing 
occurs through allosteric regulation of the EC2-
TMD4 hinge.  
 
To test this potential mechanism we mutated the 
residues necessary for these stabilising 
interactions (Fig 3). The D196A K201A mutant 
performed as expected under MD simulation: 
conformational switching occurred more 
frequently than WT CD81 despite the presence 
of cholesterol in the binding pocket. The D196A 
K201A mutant also had poor receptor activity in 
the HCVpp system and was phenotypically 
indistinguishable from the N18A E219A 
cholesterol binding mutant. Furthermore, we 
designed an additional mutant (K116A D117A) 
that, based on the work of Zimmerman et. al. 
(26), is predicted to destabilise the open 
conformation of CD81; therefore, K116A 
D117A can be considered as being opposite to 
the D196A K201A. This closed mutant of CD81 
exhibited enhanced HCV receptor activity and 
appeared to be phenotypically similar to the 
mutant with the filled cholesterol pocket (V68W 
M72W A108W V212W).  
 
The results of these experiments can be 
reconciled with a potential model of CD81 
cholesterol sensing and HCV infection. In its 
cholesterol bound state CD81 is in a closed 
conformation, it is this form of CD81 that is 
active for HCV entry. Conversely, 
conformational opening of CD81 in the absence 
of cholesterol reduces its receptor activity. 
Therefore, binding pocket mutants may 
modulate HCV entry by dysregulating 
cholesterol sensing: the E219Q and N18A 
E219A mutants reduce HCV entry by reducing 
cholesterol retention, whereas the V68W M72W 
A108W V212W enhances entry by mimicking 
cholesterol occupancy of the binding pocket. In 
this framework, the open and closed mutants act 
by decoupling conformational switching from 
cholesterol binding. The E219A mutant was 
neutral in the HCVpp assay, this is less 
consistent with the above model. However, our 
work suggests that cholesterol binding regulates 
CD81 conformation through an allosteric 
reorientation of the EC2-TMD4 hinge. 
Therefore, it is possible that the E219A mutant 
has a compensatory effect that prevents 
allosteric reorientation in the absence of 
cholesterol and, therefore, retains HCV receptor 
activity. Each of the mutated residues exhibit 
very high levels of conservation (Fig S3), which 
is consistent with their being necessary for an 
essential function, such as cholesterol sensing.  
 
We used the HCVcc system to test the mutants 
in a more physiologically relevant setting. The 
results of these experiments were largely 
consistent with the HCVpp entry assay (Fig 5) 
with one notable exception: the K116A D117A 
closed mutant did not enhance HCVcc infection. 
This disparity is most likely attributable to the 
fundamental differences between the 
constituents of HCVpp and HCVcc particles, the 
latter being associated with host lipoprotein 
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components and enriched for host-derived lipids, 
including cholesterol (62–64, 73). This may 
suggest that the lipoprotein-like properties of 
native HCV particles allow them to modulate 
CD81 cholesterol sensing. 
 
CD81 participates in a variety of cell biological 
processes through its interactions with myriad  
binding partners. We used co-IP and LFQ mass 
spectrometry to characterise the interaction 
networks of the cholesterol sensing mutants (Fig 
6). The conformational switch mutants (both 
open and closed) exhibited reduced interactions.  
This is consistent with the notion that the EC2 is 
responsible for binding partnerships and CD81 
oligomerization (72, 74, 75); moreover these 
data may suggest that EC2 conformation 
regulates protein network assembly. Notably, 
both the open and closed mutants demonstrated 
reduced interactions with known HCV co-
factors (EGFR and, to a lesser extent, Claudin-1; 
Fig. 6B). This observation does not correlate 
well with virus entry data; the closed mutant 
(K116A D117A) has robust receptor activity, 
despite reduced co-factor interactions. (Figure 3, 
4 and 5). Therefore, co-factor interactions either 
remain strong enough to not become limiting for 
HCV entry or the closed mutant’s potential 
enhancing activity (Figure 3) overcomes any 
deleterious effect from loss of interactions. 
Mutations to reduce cholesterol binding (N18A 
E219A) had a negligible effect on the 
interactome of CD81. This may indicate that 
cholesterol binding/sensing is inconsequential 
for CD81 interactions, although it is also 
possible that residual retention of cholesterol 
(Fig 1) is sufficient to allow normal partnership 
interactions. In summary the relationship 
between cholesterol sensing, protein interactions 
and HCV receptor activity remains obscure and 
will require further investigation. 
 
We did not determine why HCV entry may 
favour the closed conformation of CD81. We 
found no differences in the trafficking or cell 
surface distribution of mutant CD81, only the 
D196A K201A mutant exhibited any alteration 
in interaction with sE2 (Fig 4), and the 
interaction networks of the various mutants were 
not predictive of HCV receptor activity (Fig 6). 
Nonetheless, one might speculate on alternative 
mechanisms by which EC2 conformation 
determines receptor activity. For instance the 
close physical proximity of the closed EC2 to 
the plasma membrane may be beneficial. A 
recent report of the structure of HIV-1 gp120 in 
complex with its co-receptor CCR5 suggests that 
the principal role of CCR5 is to anchor the HIV 
fusion machinery in close apposition to the host 
membrane [63]; consequently the HIV fusion 
peptide is within striking distance upon 
activation. CD81 has been implicated in HCV 
fusion [64] and has a low profile at the cell 
surface, particularly in the closed conformation, 
therefore, it could perform an analogous 
anchoring function for the HCV glycoproteins. 
Under this mechanism, the open conformation of 
CD81 may generate an insurmountable gap 
between the viral and host membranes, 
inhibiting fusion and, therefore, entry.  
 
Notably, SR-B1 funnels cholesterol from its 
lipoprotein ligands directly into the plasma 
membrane (52, 76). Moreover, it is well 
established that HCV entry is enhanced by 
lipoproteins and that HCV particles themselves 
are lipoprotein-like being highly enriched for 
cholesterol (62–64, 73, 77). Therefore, we 
hypothesised that local delivery of cholesterol 
via SR-B1, may regulate CD81 function. 
However, co-over-expression of SR-B1 did not 
enhance cholesterol association with CD81 (Fig 
S1); this was observed in CHO cells and Huh-7 
SR-B1 KO cells. Therefore, our data do not 
support this hypothesis. Nonetheless, it remains 
possible that physiological sources of exogenous 
cholesterol, for example lipoproteins, could 
trigger CD81 cholesterol sensing; this requires 
further investigation. 
 
This study did not identify a physiological 
function of CD81 that is affected by cholesterol 
sensing; for example, CD19 trafficking was 
unaltered (Figure 4). Nonetheless, it is worth 
considering how cholesterol sensing may occur 
in the context of CD81’s natural cellular 
environment. The lipid milieu within distinct 
subcellular membranes is tightly regulated to 
impart different biophysical and functional 
properties (78). For example, whereas the 
plasma membrane is enriched for free 
cholesterol, intracellular membranes (e.g. 
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endoplasmic reticulum and Golgi apparatus) 
have 5-10 fold lower cholesterol content. 
Therefore, newly synthesised CD81 travels 
along a cholesterol concentration gradient as it 
passes through the secretory pathway to the 
plasma membrane; consequently cholesterol 
sensing is likely to occur most frequently at the 
cell surface. This provides a potential 
mechanism for regulating CD81 function in a 
location-dependent manner. Moreover, the cell 
surface does not present a homogenous lipid 
environment; phase separation results in 
microdomains enriched for different lipid 
species, including cholesterol (49). Cell surface 
proteins segregate within these lipid 
microdomains and this can alter protein function 
(79, 80). It is possible that cholesterol sensing 
determines CD81 function in a microdomain-
specific manner; indeed, there is evidence that 
CD81 can transition in and out of cholesterol-
dependent lipid domains at the cell surface (28, 
47). Therefore, cholesterol sensing may allow 
CD81 to respond to dynamic changes in the 
local lipid environment; how this might affect 
CD81’s physiological and pathological activities 
will be the focus of future research efforts. 
Experimental procedures 
Cell culture 
Huh-7 CD81 KO, and SR-B1 KO, cells were a 
kind gift from Prof. Yoshiharu Matsuura (Osaka 
University, Japan) (37). Huh-7.5 cells were 
acquired from Apath LLC. Huh-7 Lunet N cells 
were generated as previously described (81). 
HEK293T and CHO-K1 cells were acquired 
from the American Type Culture Collection. All 
cells were grown at 37°C in DMEM 
supplemented with 10% foetal calf serum, 1% 
non-essential amino acids and 1% penicillin/ 
streptomycin. 
Antibodies  
Anti-NS5 and anti-CD81 mAbs were a kind gift 
from Prof. Jane McKeating (University of 
Oxford, UK). The anti-CD81 mAbs have been 
described in detail recently (35). Anti-CD19 (sc-
19650) was purchased from Santa Cruz 
Biotechnology. StrepMAb classic was purchased 
from IBA GmbH (Göttingen, Germany). All 
secondary antibodies purchased from Thermo 
Fisher Scientific (Waltham, MA, USA). 
Lentiviral vectors 
Commercially synthesised gene sequences 
encoding WT and mutant CD81 were inserted 
into lentiviral expression plasmids by restriction 
digest. CD19 was cloned into the same 
background through PCR amplification from 
human cDNA. These plasmids will be made 
freely available after publication: 
https://www.addgene.org/Joe_Grove/. To 
generate lentiviral vectors HEK293T cells were 
co-transfected with pCMV-dR8.91 packaging 
construct, pMD2.G VSV-G expression plasmid 
and one of each of the CD81 encoding plasmids. 
Supernatants containing viral vectors were 
collected at 48 and 72 hours. The transduction 
efficiency of vectors were titrated by flow 
cytometry to allow equivalent transduction and 
expression of CD81 variants.  
HCV pseudoparticles 
HCVpp were generated in a similar manner to 
the lentiviral expression vectors. HEK293T cells 
were cotransfected with pCMV-dR8.91 
packaging construct, a luciferase reporter 
plasmid and an expression vector encoding the 
appropriate HCV glycoprotein. Supernatants 
containing HCVpp were collected at 48 and 72 
hours. UKN4.1.1, 5.2.1, 2A1.2 and 2B1.1 E1E2 
expression plasmids were kindly provided by 
Alex Tarr and Jonathan Ball (University of 
Nottingham, UK), all other E1E2 plasmids were 
generated in-house through PCR or commercial 
gene synthesis. 
Cell culture proficient HCV 
HCVcc were generated as described previously 
(36). Briefly, in vitro transcribed full-length 
HCV RNA genomes were electroporated into 
Huh-7.5 cells. Supernatants containing 
infectious HCVcc were harvested every 2-4 
hours during the day, from 3-7 days post 
electroporation. Harvests were then pooled, 
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aliquoted and frozen to generate a standardised 
stock for infection assays. 
Infections  
Huh-7 or Huh-7 Lunet N cells were seeded into 
96 well plates 24 hours prior to the experiment; 
to infect they were challenged with 
HCVpp/HCVcc supernatants (diluted 1/2 – 1/4 
in DMEM 6% FCS). The infections were 
allowed to proceed for 72 hours before read out. 
For HCVpp, the samples were lysed and assayed 
using the SteadyGlo reagent kit and a GloMax 
luminometer (Promega, Maddison, WI, USA). 
To measure HCVcc replication, cells were fixed 
with 100% methanol and stained for viral NS5 
protein, the proportion of infected cells was 
determined using the ImageJ Infection Counter 
plugin (82), these data were also verified by 
manually counting foci forming units. For 
HCVcc encoding a Renilla luciferase reporter, 
cells were lysed with milli-Q water and frozen at 
-80 °C to ensure complete lysis, the samples 
were transferred to 96 wells-white plates and 
mixed with Renilla luciferase substrate solution 
(Coelenterazine, 0.42 mg/ml in Methanol) and 
luciferase activity was determined using a 
microplate reader Centro XS (Berthold 
Technologies, Harpenden, UK).    
Subgenomic replicon system 
SGR transcripts were generated by in vitro 
transcription and introduced into target cells by 
electroporation (as with HCVcc). Replication 
was assessed at 4 and 24 hours post 
electroporation by read out of a genetically 
encoded Renilla luciferase reporter, as described 
above. 
Flow cytometry 
To measure cell surface expression of CD81 or 
CD19, single-cell suspensions of Huh-7/CHO 
cells were fixed in 1% formaldehyde and then 
blocked in PBS + 1% BSA. All subsequent steps 
are performed in blocking buffer. Cells (100µl at 
1-3x106/ml) were then serially incubated with 
anti-receptor antibodies followed by anti-mouse 
Alexa Fluor 647 secondary, 1 hour incubation 
each at room temperature. Fluorescence signals 
were measured on a LSR Fortessa (BD, Franklin 
Lakes, NJ, USA) and data was analysed using 
FlowJo (FlowJo LLC, Ashland, OR, USA). The 
lentiviral vectors, described above, also express 
GFP (from a separate promoter); therefore, this 
GFP signal was used as an independent measure 
of transduction to identify positive cells during 
analysis.  
Immunoprecipitation and cholesterol 
association assay 
Huh7 CD81 KO cells were transduced to 
express various CD81 cholesterol-binding 
mutants. To perform the pull-down, a confluent 
T150cm2 flask of cells were trypsinized, 
harvested and resuspended in ‘traffic stop’ 
buffer, PBS + 1% bovine serum albumin (BSA) 
and 0.01% sodium azide; this depletes cellular 
ATP pools, consequently preventing receptor 
internalisation (60). The resuspended cells were 
then incubated with anti-CD81 mAb 2.131 at 
1ug/ml for 60 minutes. Cells were washed with 
PBS and then lysed in 1% Brij58 buffer (1% 
Brij58, 20mM Tris pH 7.5, 150mM NaCl, 1mM 
CaCl2, 1mM MgCl2 and 0.02% NaN3) plus 1X 
protease inhibitor for 30 minutes. All steps were 
carried out on ice. Lysates were centrifuged at 
13,300 rpm for 12 minutes at 4°C and then 
incubated with protein G sepharose beads for 90 
minutes on a tube rotator in the cold room. 
Finally, beads were washed and stored at -20°C 
in 1% Brij58 buffer until further analysis.  
 
We quantified cholesterol associated with CD81 
using an Amplex Red Cholesterol Assay 
(Thermo Fisher Scientific, Waltham, MA, 
USA). Beads were pelleted by centrifugation, 
resuspended in 1X reaction buffer (as described 
by the manufacturer) and incubated in a tube 
rotator at room temperature for 15 minutes, this 
step extracts cholesterol associated with the 
immunocomplexes. Beads were then centrifuged 
and the supernatant was diluted 1/2 in 1X 
reaction buffer to a total volume of 50µl. 
Samples were incubated with 50ul working 
solution of Amplex Red Reagent at 37°C; 
cholesterol esterase was omitted from the CD81 
samples to ensure the measurement of free-
cholesterol only. Signal was measured using the 
fluorescence plate reading capability of a real-
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time PCR machine (Bio Rad, Hercules, CA, 
USA). A standard curve was prepared through 
serial dilution of the cholesterol reference in 1X 
reaction buffer, allowing the concentration of 
cholesterol to be determined in the positive 
control and CD81 samples. 
Western Blot 
One day prior to study, Huh-7 cells +/- CD81 
and/or CD19 were seeded into standard 24 well 
plates at 4x104 cells/well. Cells were then lysed 
using a buffer containing 20mM Tris-HCl, 
135mM NaCl, 1% Triton-X 100 and 10% 
glycerol. The samples were then run on a 
TruPage 4-12% gel under non-reducing 
conditions and transferred on to nitrocellulose 
membrane. The blots were blocked in PBS + 2% 
milk solution + 0.1% Tween-20 and then probed 
by serial incubation with anti-receptor antibodies 
and goat anti-mouse secondary conjugated to 
horseradish peroxidase. Chemiluminescence 
signal was then measured in a Chemidoc MP 
(Bio Rad, Hercules, CA, USA). 
Microscopy 
One day prior to study, Huh-7 cells +/- CD81 
and/or CD19 were seeded into standard 24 well 
plates at 1.2x104 cells/well. Cells were then 
fixed (in situ) in 2% formaldehyde, blocked and 
stained, as described for flow cytometry, with 
the inclusion of a 10 minute DAPI counterstain 
at the end of the procedure. Samples were 
imaged on a Nikon Ti inverted microscope, 
through a 40X extra-long working distance 
objective, using a C2 confocal scan head with 
405nm and 635nm laser illumination (Nikon 
Instruments, Tokyo, Japan). Multiple Z-stacks 
were acquired for each sample. Data was 
processed for display using FIJI/ImageJ (83, 84). 
Soluble E2 binding assay 
J6 and H77 E2 ectodomains (residues 384-661) 
were PCR cloned into expression vectors, as 
previously described (60), with the resultant 
constructs including an upstream tissue 
plasminogen activator signal sequence (to direct 
efficient secretion) and a downstream strep-tag 
II (for detection and purification). Proteins were 
produced by transient transfection of HEK293T 
cells with the supernatants being harvested at 48 
and 72 hours post infection. sE2 was purified 
using a Strep-Tactin column (IBA Life 
Sciencens, Göttingen, Germany), monomeric 
sE2 was subsequently isolated by size exclusion 
chromatography. The sE2 binding assay was 
performed as previously described. A single-cell 
suspension of CHO +/- CD81 cells were 
preincubated in ‘traffic stop’ buffer, described 
above. All subsequent steps are performed in 
traffic stop buffer. Cells (100µl at 1-3x106/ml) 
were then mixed with 10µg/ml sE2 and 
incubated for 1 hour at 37°C. Bound sE2 was 
then detected using 3µg/ml StrepMab classic 
followed by an anti-mouse Alexa Fluor 647 
secondary, 1 hour incubation each at room 
temperature. Finally, cells were fixed in 1% 
formaldehyde. Fluorescence signals were 
measured by flow cytometry.  
Co-immunoprecipitation and LC-MS/MS 
analysis 
To identify CD81 interaction partners, Huh-7 
Lunet N cells expressing CD81 (WT or mutant) 
or empty vector control were harvested from a 
90% confluent T150cm2 plate by scraping. 
Experiments were conducted in four biological 
replicates from four independent cell passages. 
Cells were lysed in Brij58 buffer (1% Brij 58, 50 
mM Hepes, pH 7.4, 150 mM NaCl, 10 % 
glycerol, 1 mM CaCl2) supplemented with 1x 
protease and phosphatase inhibitors for 30 min 
on ice. Nuclear debris was pelleted at 12000g for 
10 minutes at 4°C followed by co-
immunoprecipitation using Pierce Crosslink 
Immunoprecipitation kit (Thermo Fisher 
Scientific, Waltham, MA, USA) with 
crosslinked anti-CD81 (clone 1.3.3.22, Santa 
Cruz). Efficiency of bait enrichment was 
determined by western blot using anti-CD81 
(JS-81, BD Biosciences).  
 
The co-IP samples were reduced, alkylated and 
trypsinized as previously described (7). Peptide 
mixtures were analysed using a nanoflow liquid 
chromatography (LC-MS/MS) on an EASY-
nLC 1000 system (Thermo Fisher Scientific) 
coupled to a Q Exactive HF-X Quadrupole-
Orbitrap mass spectrometer (Thermo Fisher 
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Scientific). A column oven (Sonation) 
maintained the temperature at 60°C. 500 ng 
peptide samples in buffer A (0.1% formic acid) 
were loaded onto a 50-cm column with 75-µm 
inner diameter, packed with C18 1.9 µm 
ReproSil beads (Dr Maisch GmbH). Peptides 
were separated chromatographically with a 
95 min gradient from 5% to 30% buffer B (80% 
acetonitrile, 0.1% formic acid). 
The MS was operated in data-dependent 
acquisition mode, where one full scan (300 to 
1650 m/z, R = 60000 at 200 m/z) at a target of 
3x106 ions is followed by 15 data-dependent 
MS/MS scans with higher energy collisional 
dissociation [target 105 ions, max ion fill time 28 
ms, isolation window 1.4 m/z, normalized 
collision energy 27%, R = 15000 at 200 m/z]. 
Dynamic exclusion of 30 s was enabled. 
MS raw files were processed in MaxQuant 
(Version 1.6.2.0; (85)) and peptide fragment lists 
were searched against the human FASTA 
Uniprot reference proteome (June 2019; 20415 
entries without isoforms (UP000005640), 42411 
with isoforms (UP000005640(1))) by the built-
in Andromeda search engine. We restricted 
enzyme specificity with cleavage C-terminal 
after K or R (trypsin and Lys-C), allowing up to 
two missed cleavages. Precursor mass tolerance 
was set to 20ppm, fragment mass tolerance was 
set to 4.5ppm. Fixed modifications of cysteine 
carbamidomethylation and variable 
modifications for the N-acetylation of proteins 
and the oxidation of methionine were specified. 
The minimum peptide length was set to seven 
amino acids. False discovery rates (FDRs) at the 
peptide and protein levels were 1%. The label-
free-quantification (MaxLFQ) and matching 
between runs features were enabled.  
Protein groups were filtered for decoys, 
contaminants and modifications. Data was also 
filtered for valid values (3, in at least one group). 
Protein identification data is provided in 
Supplementary File 2. Interaction profiles were 
analysed with imputation of missing values 
(Width: 0.3, down shift: 1.8). Statistical analysis 
of proteomics data was conducted using two-
sample t-test comparing LFQ intensities of 
proteins found in CD81 WT or mutants, against 
empty vector control (FDR: 0.05, s0=1). The 
resulting protein interactions have been 
submitted to the IMEx 
(http://www.imexconsortium.org) consortium 
through IntAct (86) with the assigned identifier 
IM-28053. The mass spectrometry proteomics 
data have been deposited to the 
ProteomeXchange Consortium via the PRIDE 
partner repository (87) with the dataset identifier 
PXD019260. 
 
Molecular dynamics simulations 
We started with a molecular model of full-length 
CD81 in a closed conformation; this is based on 
the crystal structure (5TCX), as previously 
described, and was generously provided by Prof. 
Ron O. Dror and Dr. Brendan Kelly. All 
substitutions were introduced using Modeller 
software and AutoSub.py script available at 
https://github.com/williamdlees/AmberUtils. 
Protonation states were determined in 
MolProbity(88). There are three histidine 
residues (37, 151, 191) within the CD81. In the 
models of WT without cholesterol and D196A 
K201A with cholesterol, all histidines were 
protonated on the epsilon nitrogen. In the WT 
with cholesterol model, the histidines 37 and 
191 were also protonated on the epsilon nitrogen 
and the histidine 151 was protonated on the delta 
nitrogen. Models were then inserted into 
simulated palmitoyl-oleoyl-phosphatidylcholine 
(POPC) bilayers using CHARMM-GUI (88, 89). 
  
For MD simulations, each variant model was put 
through the same pipeline. First, the models 
were solvated in a rectangular box using TIP3 
water molecules and 0.15 M of NaCl. The 
volume of the box was ~5x105Å3 with the total 
of ~5.2 x 104 atoms including around 128 lipid 
molecules. The CHARMM 36 force field was 
used for the simulations on GPUs using the 
CUDA version of PMEMD in Amber 18(90–
92). The systems were minimised by 2500 steps 
of steepest descent followed by 2500 steps of the 
conjugate gradient method with all protein 
atoms restrained by a force of 10 kcal/mol/Å2 
and phosphate atoms of the POPC bilayer by a 
force of 2.5 kcal/mol/Å2. The systems were then 
heated to 310 K for 25 ps using the Langevin 
thermostat under constant volume whilst 
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keeping the identical restraints, followed by 
further 25 ps with the protein atoms restrained 
by 5 kcal/mol/Å2 and the phosphate atoms of the 
POPC bilayer by a force of 2.5 kcal/mol/Å2. 
Initial velocities were sampled from Boltzmann 
distribution. 
 
Further equilibration was performed under 
constant pressure (1bar) using the Monte Carlo 
barostat and semi-isotropic pressure coupling for 
25 ps with the protein atoms restrained by 2.5 
kcal/mol/Å2 and the phosphate atoms of the 
POPC bilayer by a force of 1 kcal/mol/Å2. This 
was followed by additional three equilibration 
steps lasting 100 ps each under constant pressure 
using the Monte Carlo barostat and semi-
isotropic pressure coupling with the protein 
atoms decreasing to 1, 0.5 and 0.1 kcal/mol/Å2 
and the phosphate atom restraints decreasing to 
0.5, 0.1 and 0 restraints kcal/mol/Å2 
respectively. 
  
Following minimisation and equilibration steps, 
500ns production runs were simulated under 
constant pressure using the Monte Carlo 
barostat, semi-isotropic pressure coupling and 
constant temperature via the Langevin 
thermostat at 310 K. For each independent 
simulation the restart file from the final 
equilibration step was used as the input for a 
short (1ns) production run but only the 
coordinates, not the velocity, were used to de-
correlate the simulation. The coordinates from 
this short run were then used as input for the 
500ns production run. 
  
1 fs time step was used for minimisation, and the 
first two equilibration steps. SHAKE was used 
in order to restrain hydrogen bonds in all but the 
minimisation steps and 2 fs time-step was used 
for the last four equilibration and production 
runs.  For all simulations,  the cutoff distance for 
Lennard-Jones (LJ) 6-12 interactions was set to 
be 12 Å. The LJ 6-12 were smoothed over the 
range of 10 to 12 Å using the force-based 
switching function. Particle mesh Ewals (PME) 
method was used for the long-range electrostatic 
interactions and 1-4 nonbonded interactions 
were not scaled. To avoid the overflow of 
coordinates, the iwrap was set to 1.   
Sequence conservation analysis 
Vertebrate CD81 encoding gene sequences were 
pulled from the NCBI database. Multiple 
sequence alignment and phylogenetic tree 
construction (using representative gene 
sequences) was performed using CLC sequence 
viewer (Qiagen, Hilden, Germany). 
Molecular modeling  
Molecular graphics and analyses performed with 
UCSF Chimera, developed by the Resource for 
Biocomputing, Visualization, and Informatics at 
the University of California, San Francisco, with 
support from NIH P41-GM103311 (93). 
Statistical analysis 
All statistical analysis was performed in 
GraphPad Prism 6.0 (San Diego, USA). 
Ordinary one-way ANOVA was performed 
using Dunnett’s multiple comparison test, using 
WT CD81 as a control, unless stated otherwise. 
Unpaired t-test was performed assuming equal 
standard deviation using a two-tailed p-value. 
Data availability 
The raw mass spectrometry proteomics data 
have been deposited to the ProteomeXchange 
Consortium and can be accessed here: 
http://proteomecentral.proteomexchange.org/cgi/
GetDataset?ID=PXD019260. The protein 
interaction results are available from IMEx: 
https://www.ebi.ac.uk/intact/pages/interactions/i
nteractions.xhtml?query=pubid:IM-28053. 
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Figure Legends 
Fig. 1. Mutations in the cholesterol binding pocket of CD81 modulate HCV entry. A. Cholesterol 
(red) is coordinated in the intramembrane cavity of CD81 by hydrogen bonds with inward facing residues 
N18 and E219. We made various mutations at these sites to disrupt this interaction. B. The cholesterol 
molecule sits in the centre of an intramembrane binding pocket. In the V68W M72W A108W V212W 
mutant this space is occupied by tryptophan residues (blue residues). Molecular model images created 
using PDB 5TCX (26) C. The cell surface expression levels of each mutant CD81 was assessed by flow 
cytometry. D. Huh-7 CD81 KO cells were transduced with lentivector encoding WT CD81 or empty 
vector control. The cells were surface labelled with anti-CD81 mAb and lysed in Brij-98 detergent buffer. 
CD81-mAb complexes were pulled-down with protein G beads and associated free cholesterol was 
measured. The negative control represents pull-down from cells transduced with empty vector control. 
The positive control contains 0.31µM exogenous cholesterol, and demonstrates the accuracy of the assay. 
The dashed line indicates the limit of detection E. We assessed cholesterol association with WT and 
mutant CD81. Data is expressed relative to WT CD81, asterisks indicate statistical significance from WT 
(n=4, one-way ANOVA, Prism). The western blot demonstrates equivalent levels of CD81 in the whole 
cell lysate (WCL) and pull-down (IP) F. Huh-7 CD81 KO cells were transduced with lentivectors 
encoding WT and mutant CD81, cell surface expression was confirmed by flow cytometry, as in C.. HCV 
entry was assessed by challenge with a panel of HCVpp (including genotypes 1, 2 and 5). HCVpp 
infection, for three representative clones, is shown relative to cells expressing WT CD81 (n=4). G. 
Summary data displaying mean relative infection, as in E., for six HCVpp clones. Asterisks indicate 
statistical significance from WT (one-way ANOVA, Prism), error bars indicate standard deviation of the 
mean.  
 
Figure 2. Conformational switching of CD81 in the absence of cholesterol. We performed five 
independent 500ns MD simulations of WT CD81 with and without cholesterol. A. Snapshots 
summarising representative simulations from either condition. The Δ° measurement reflects the change in 
the angle between helix E of the EC2 and TMD4 (as annotated), by comparison to the CD81 crystal 
structure (PDB 5TCX). For each snapshot the region from which the measurement was taken is color-
coded by time. Cholesterol is shown in red. Structures were orientated using TMD4 as a reference. 
Examples of the orientation of D196 and K201 are shown as insets. B. The angle between helix E and 
TMD4 was measured over time for each simulation, 25° was chosen as a threshold to indicate 
conformational switching. C. The cumulative time spent in the open conformation was calculated across 
all simulations for either experimental condition. D. The distance between D196 K201 was measured over 
time for each simulation, the dashed line indicates the distance under which electrostatic interactions and 
hydrogen bonding occurs (10Å). E. The average distance between D196 and K201 with and without 
cholesterol, data points represent the mean value for each simulation, the asterisk indicates statistical 
significance (n=5 simulations, unpaired T-test, Prism), error bars indicate standard deviation of the mean. 
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Figure 3. Conformational switch mutants modulate HCV entry. We mutated residues D196 and K201 
to prevent stabilizing interactions across the EC2-TMD4 hinge. A. We performed five independent MD 
simulations of WT and D196A K201A CD81 in the presence of cholesterol. Images provide overlaid 
snapshots from representative simulations. Helix E, TMD4 and cholesterol are color coded by time. For 
clarity the remaining structure is shown in grey for the t=0ns snapshot only. Structures were orientated 
using TMD4 as a reference B. The change in angle between Helix E and TMD4, by comparison to the 
CD81 crystal structure, was measured over time for each D196A K201A simulation; compare to Fig 2B. 
The cumulative time spent in the open conformation across all simulations was 400ns for WT and 1050ns 
for D196A K201A.  C. The average distance between residues 196 and 201 for WT and D196A K201A 
in the presence of cholesterol, the dashed line indicates the distance under which electrostatic interactions 
and hydrogen bonding can occur (10Å). Data points represent the mean value for each simulation, the 
asterisk indicates statistical significance (n=5 simulations, unpaired T-test, Prism). D. Huh-7 CD81 KO 
cells were transduced with lentivectors encoding WT CD81, N18A E219A (cholesterol binding mutant), 
D196A K201A (open mutant) or K116A D117A (closed mutant), equal cell surface expression was 
confirmed by flow cytometry (representative data is provided in Figure 4). HCV entry was assessed by 
challenge with a panel of HCVpp (including genotypes 1, 2, 4 and 5). HCVpp infection, from three 
representative clones, is shown relative to cells expressing WT CD81. Asterisks indicate statistical 
significance from WT (n=4, one-way ANOVA, Prism). There was no significant difference between 
N18A E219A and D196A K201A. E. Summary data displaying mean relative infection, as in D., for eight 
HCVpp clones. Asterisks indicate statistical significance from WT (n=8, one-way ANOVA, Prism). In all 
plots error bars indicate standard deviation of the mean.  
 
Figure 4. Cell surface functionality of CD81 mutants. Huh-7 CD81 KO cells were co-transduced with 
lentivectors encoding human CD19 and CD81 or empty vector. A. Representative flow cytometry 
histograms, all samples received CD19 lentivector plus the indicated CD81/control vector. The plot on the 
left demonstrates CD81 surface expression (i), the right-hand plot displays CD81-dependent trafficking of 
CD19 to the cell surface (ii). B. CD81 expression on CHO cells confers binding on soluble HCV E2. The 
plot on the left demonstrates CD81 surface expression (i), the right-hand plot displays sE2 binding to 
transduced CHO cells (ii). C. Quantification of sE2 binding expressed relative to WT CD81. Asterisks 
indicate statistical significance from WT (n=3, one-way ANOVA, Prism). Error bars indicate standard 
deviation of the mean. 
 
Figure 5. Cholesterol sensing is important for authentic HCV infection. Huh-7 CD81 KO cells were 
transduced with lentivectors expressing the stated CD81 mutants and were then challenged with J6/JFH 
HCVcc. Equal cell surface expression of WT and mutant CD81 was confirmed by flow cytometry 
(representative data is provided in Figure 4) A. Representative micrographs of HCVcc infection in 
transduced cells; DAPI nuclei shown in blue, viral antigen NS5A displayed in orange, scale bar = 100µ 
m. B. Quantification of infection, data is expressed relative to infection in cells expressing WT CD81, 
asterisks indicate statistical significance from WT (n=4, one-way ANOVA, Prism). C. Huh-7 Lunet N 
cells stably expressing the stated CD81 mutants were challenged with a panel of diverse HCVcc bearing 
the glycoproteins of genotypes 1, 2, 3, 4 and 5. Infection was quantified via a virally encoded luciferase 
reporter and is shown, relative to WT CD81, for three representative clones. Asterisks indicate statistical 
significance from WT (n=3, one-way ANOVA, Prism). D. Summary data displaying mean relative 
infection, as in C., for twelve HCVcc chimeras. Asterisks indicate statistical significance from WT (n=12 
one-way ANOVA, Prism). In all plots error bars indicate standard deviation of the mean.  
 
Figure 6. Conformational switch mutants exhibit altered protein interaction networks. A. Volcano 
plot visualizing differences from co-IPs of Huh-7 Lunet N CD81 WT versus Lunet N control cells (n=4 
biological replicates for each cell line). LFQ intensity differences (log2) are plotted against the t-test p 
value (-logP). Significant interactors were defined by a permutation-based FDR using S0=1 as described 
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[94]. Reference proteins (CD81, SCARB1, CLDN1, EGFR, TFRC, CAPN5 ITGB and CD151) are 
highlighted, color coded as in B. B. Mean LFQ intensity differences (log2) of interactors in CD81 co-IP 
(Huh-7 Lunet N CD81 WT and mutants versus Lunet N control cells). Error bars indicate standard 
deviation of the mean (n=4) C. Venn diagrams showing the overlap of significantly enriched proteins 
found in CD81 co-IPs from WT in grey, N18A E219A (Chl) in orange, D196A K201A (O) in purple and 
K116A D117A (C) in green. Values below each title indicate significant interactors for each CD81 
variant, values in the center of each Venn diagram indicate overlapping interactors. 
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Fig.	1.	Mutations	in	the	cholesterol	binding	pocket	of	CD81	modulate	HCV	entry.	A.	Cholesterol	(red)	is	
coordinated	in	the	intramembrane	cavity	of	CD81	by	hydrogen	bonds	with	inward	facing	residues	N18	
and	E219.	We	made	various	mutations	at	these	sites	to	disrupt	this	interaction.	B.	The	cholesterol	
molecule	sits	in	the	centre	of	an	intramembrane	binding	pocket.	In	the	V68W	M72W	A108W	V212W	
mutant	this	space	is	occupied	by	tryptophan	residues	(blue	residues).	Molecular	model	images	created	
using	PDB	5TCX	(26)	C.	The	cell	surface	expression	levels	of	each	mutant	CD81	was	assessed	by	flow	
cytometry.	D.	Huh-7	CD81	KO	cells	were	transduced	with	lentivector	encoding	WT	CD81	or	empty	vector	
control.	The	cells	were	surface	labelled	with	anti-CD81	mAb	and	lysed	in	Brij-98	detergent	buffer.	CD81-
mAb	complexes	were	pulled-down	with	protein	G	beads	and	associated	free	cholesterol	was	measured.	
The	negative	control	represents	pull-down	from	cells	transduced	with	empty	vector	control.	The	positive	
control	contains	0.31µM	exogenous	cholesterol,	and	demonstrates	the	accuracy	of	the	assay.	The	
dashed	line	indicates	the	limit	of	detection	E.	We	assessed	cholesterol	association	with	WT	and	mutant	
CD81.	Data	is	expressed	relative	to	WT	CD81,	asterisks	indicate	statistical	significance	from	WT	(n=4,	
one-way	ANOVA,	Prism).	The	western	blot	demonstrates	equivalent	levels	of	CD81	in	the	whole	cell	
lysate	(WCL)	and	pull-down	(IP)	F.	Huh-7	CD81	KO	cells	were	transduced	with	lentivectors	encoding	WT	
and	mutant	CD81,	cell	surface	expression	was	confirmed	by	flow	cytometry,	as	in	C..	HCV	entry	was	
assessed	by	challenge	with	a	panel	of	HCVpp	(including	genotypes	1,	2	and	5).	HCVpp	infection,	for	three	
representative	clones,	is	shown	relative	to	cells	expressing	WT	CD81	(n=4).	G.	Summary	data	displaying	
mean	relative	infection,	as	in	E.,	for	six	HCVpp	clones.	Asterisks	indicate	statistical	significance	from	WT	
(one-way	ANOVA,	Prism),	error	bars	indicate	standard	deviation	of	the	mean.		
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Figure	 2.	 Conformational	 switching	 of	 CD81	 in	 the	 absence	 of	 cholesterol.	 We	 performed	 five	
independent	 500ns	 MD	 simulations	 of	 WT	 CD81	 with	 and	 without	 cholesterol.	 A.	 Snapshots	
summarising	representative	simulations	from	either	condition.	The	Δ°	measurement	reflects	the	change	
in	the	angle	between	helix	E	of	the	EC2	and	TMD4	(as	annotated),	by	comparison	to	the	CD81	crystal	
structure	 (PDB	5TCX).	For	each	snapshot	 the	 region	 from	which	 the	measurement	was	 taken	 is	 color-
coded	 by	 time.	 Cholesterol	 is	 shown	 in	 red.	 Structures	 were	 orientated	 using	 TMD4	 as	 a	 reference.	
Examples	of	 the	orientation	of	D196	and	K201	are	shown	as	 insets.	B.	The	angle	between	helix	E	and	
TMD4	 was	 measured	 over	 time	 for	 each	 simulation,	 25°	 was	 chosen	 as	 a	 threshold	 to	 indicate	
conformational	switching.	C.	The	cumulative	time	spent	in	the	open	conformation	was	calculated	across	
all	 simulations	 for	 either	 experimental	 condition.	D.	The	distance	between	D196	K201	was	measured	
over	 time	 for	 each	 simulation,	 the	 dashed	 line	 indicates	 the	 distance	 under	 which	 electrostatic	
interactions	and	hydrogen	bonding	occurs	(10Å).	E.	The	average	distance	between	D196	and	K201	with	
and	 without	 cholesterol,	 data	 points	 represent	 the	 mean	 value	 for	 each	 simulation,	 the	 asterisk	
indicates	 statistical	 significance	 (n=5	 simulations,	unpaired	T-test,	 Prism),	 error	bars	 indicate	 standard	
deviation	of	the	mean.	
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Figure	3.	Conformational	switch	mutants	modulate	HCV	entry.	We	mutated	residues	D196	and	K201	to	
prevent	 stabilizing	 interactions	 across	 the	 EC2-TMD4	 hinge.	 A.	 We	 performed	 five	 independent	 MD	
simulations	 of	 WT	 and	 D196A	 K201A	 CD81	 in	 the	 presence	 of	 cholesterol.	 Images	 provide	 overlaid	
snapshots	from	representative	simulations.	Helix	E,	TMD4	and	cholesterol	are	color	coded	by	time.	For	
clarity	the	remaining	structure	is	shown	in	grey	for	the	t=0ns	snapshot	only.	Structures	were	orientated	
using	TMD4	as	a	 reference	B.	 The	change	 in	angle	between	Helix	E	and	TMD4,	by	 comparison	 to	 the	
CD81	crystal	structure,	was	measured	over	time	for	each	D196A	K201A	simulation;	compare	to	Fig	2B.	
The	 cumulative	 time	 spent	 in	 the	 open	 conformation	 across	 all	 simulations	 was	 400ns	 for	 WT	 and	
1050ns	for	D196A	K201A.	 	C.	The	average	distance	between	residues	196	and	201	for	WT	and	D196A	
K201A	in	the	presence	of	cholesterol,	the	dashed	line	 indicates	the	distance	under	which	electrostatic	
interactions	 and	 hydrogen	 bonding	 can	 occur	 (10Å).	 Data	 points	 represent	 the	mean	 value	 for	 each	
simulation,	 the	 asterisk	 indicates	 statistical	 significance	 (n=5	 simulations,	 unpaired	 T-test,	 Prism).	D.	
Huh-7	CD81	KO	 cells	were	 transduced	with	 lentivectors	 encoding	WT	CD81,	N18A	E219A	 (cholesterol	
binding	 mutant),	 D196A	 K201A	 (open	 mutant)	 or	 K116A	 D117A	 (closed	 mutant),	 equal	 cell	 surface	
expression	was	 confirmed	by	 flow	 cytometry	 (representative	data	 is	 provided	 in	 Figure	4).	HCV	entry	
was	assessed	by	challenge	with	a	panel	of	HCVpp	(including	genotypes	1,	2,	4	and	5).	HCVpp	infection,	
from	 three	 representative	 clones,	 is	 shown	 relative	 to	 cells	 expressing	 WT	 CD81.	 Asterisks	 indicate	
statistical	 significance	 from	 WT	 (n=4,	 one-way	 ANOVA,	 Prism).	 There	 was	 no	 significant	 difference	
between	N18A	E219A	and	D196A	K201A.	E.	Summary	data	displaying	mean	relative	infection,	as	in	D.,	
for	eight	HCVpp	clones.	Asterisks	indicate	statistical	significance	from	WT	(n=8,	one-way	ANOVA,	Prism).	
In	all	plots	error	bars	indicate	standard	deviation	of	the	mean.		
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Figure	 4.	 Cell	 surface	 functionality	 of	 CD81	mutants.	Huh-7	 CD81	 KO	 cells	 were	 co-transduced	with	
lentivectors	 encoding	 human	 CD19	 and	 CD81	 or	 empty	 vector.	 A.	 Representative	 flow	 cytometry	
histograms,	all	 samples	received	CD19	 lentivector	plus	 the	 indicated	CD81/control	vector.	The	plot	on	
the	 left	 demonstrates	 CD81	 surface	 expression	 (i),	 the	 right-hand	 plot	 displays	 CD81-dependent	
trafficking	of	CD19	to	the	cell	 surface	 (ii).	B.	CD81	expression	on	CHO	cells	confers	binding	on	soluble	
HCV	E2.	The	plot	on	the	left	demonstrates	CD81	surface	expression	(i),	the	right-hand	plot	displays	sE2	
binding	 to	 transduced	 CHO	 cells	 (ii).	C.	 Quantification	 of	 sE2	 binding	 expressed	 relative	 to	WT	 CD81.	
Asterisks	 indicate	 statistical	 significance	 from	WT	 (n=3,	 one-way	 ANOVA,	 Prism).	 Error	 bars	 indicate	
standard	deviation	of	the	mean.	
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Figure	 5.	 Cholesterol	 sensing	 is	 important	 for	 authentic	 HCV	 infection.	 Huh-7	 CD81	 KO	 cells	 were	
transduced	with	lentivectors	expressing	the	stated	CD81	mutants	and	were	then	challenged	with	J6/JFH	
HCVcc.	 Equal	 cell	 surface	 expression	 of	 WT	 and	 mutant	 CD81	 was	 confirmed	 by	 flow	 cytometry	
(representative	 data	 is	 provided	 in	 Figure	 4)	 A.	 Representative	 micrographs	 of	 HCVcc	 infection	 in	
transduced	cells;	DAPI	nuclei	shown	in	blue,	viral	antigen	NS5A	displayed	in	orange,	scale	bar	=	100μ	m.	
B.	 Quantification	 of	 infection,	 data	 is	 expressed	 relative	 to	 infection	 in	 cells	 expressing	 WT	 CD81,	
asterisks	indicate	statistical	significance	from	WT	(n=4,	one-way	ANOVA,	Prism).	C.	Huh-7	Lunet	N	cells	
stably	expressing	the	stated	CD81	mutants	were	challenged	with	a	panel	of	diverse	HCVcc	bearing	the	
glycoproteins	 of	 genotypes	 1,	 2,	 3,	 4	 and	 5.	 Infection	was	 quantified	 via	 a	 virally	 encoded	 luciferase	
reporter	and	is	shown,	relative	to	WT	CD81,	for	three	representative	clones.	Asterisks	indicate	statistical	
significance	 from	 WT	 (n=3,	 one-way	 ANOVA,	 Prism).	 D.	 Summary	 data	 displaying	 mean	 relative	
infection,	as	 in	C.,	 for	twelve	HCVcc	chimeras.	Asterisks	 indicate	statistical	significance	from	WT	(n=12	
one-way	ANOVA,	Prism).	In	all	plots	error	bars	indicate	standard	deviation	of	the	mean.		
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Figure	6.	Conformational	switch	mutants	exhibit	altered	protein	interaction	networks.	A.	Volcano	plot	
visualizing	differences	from	co-IPs	of	Huh-7	Lunet	N	CD81	WT	versus	Lunet	N	control	cells	(n=4	biological	
replicates	for	each	cell	line).	LFQ	intensity	differences	(log2)	are	plotted	against	the	t-test	p	value	(-logP).	
Significant	 interactors	 were	 defined	 by	 a	 permutation-based	 FDR	 using	 S0=1	 as	 described	 [94].	
Reference	proteins	(CD81,	SCARB1,	CLDN1,	EGFR,	TFRC,	CAPN5	ITGB	and	CD151)	are	highlighted,	color	
coded	as	in	B.	B.	Mean	LFQ	intensity	differences	(log2)	of	interactors	in	CD81	co-IP	(Huh-7	Lunet	N	CD81	
WT	and	mutants	versus	Lunet	N	control	cells).	Error	bars	indicate	standard	deviation	of	the	mean	(n=4)	
C.	Venn	diagrams	showing	the	overlap	of	significantly	enriched	proteins	found	in	CD81	co-IPs	from	WT	in	
grey,	N18A	E219A	 (Chl)	 in	orange,	D196A	K201A	 (O)	 in	purple	 and	K116A	D117A	 (C)	 in	 green.	Values	
below	each	title	indicate	significant	interactors	for	each	CD81	variant,	values	in	the	center	of	each	Venn	
diagram	indicate	overlapping	interactors.	
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